Onychomycosis: Diagnosis and definition of cure

Journal of the American Academy of Dermatology

Volumn 56, Issue 6, 2007, Pages 939-944

  Scher, Richard K ^a   Tavakkol, Amir ^b   Sigurgeirsson, Bárdur ^c   Hay, Roderick J ^d   Joseph, Warren S ^e   Tosti, Antonella ^f   Fleckman, Philip ^g   Ghannoum, Mahmoud ^h   Armstrong, David G ⁱ   Markinson, Bryan C ^j   Elewski, Boni E ^k  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF ICELAND   (Iceland)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Rosalind Franklin University of Medicine and Science Dr William M Scholl College of Podiatric Medicine   (United States)

^j MOUNT SINAI MEDICAL CENTER   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ARTICLE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; HUMAN; LABORATORY DIAGNOSIS; NAIL BED; ONYCHOMYCOSIS; PRIORITY JOURNAL; RECURRENT DISEASE;

COLOR; HUMANS; HYPERTROPHY; NAILS; ONYCHOMYCOSIS; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 34248342980     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.12.019     Document Type: Article

References (27)

1. Elewski B.E., and Charif M.A. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 133 (1997) 1172-1173
2. Roberts D.T. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 126 Suppl (1992) 23-27
3. Sais G., Jucgla A., and Peyri J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 132 (1995) 758-761
4. Heikkila H., and Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 133 (1995) 699-703
5. Svejgaard E.L., and Nilsson J. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses 47 (2004) 131-135
6. Sigurgeirsson B., Steingrimsson O., and Sveinsdottir S. Prevalence of onychomycosis in Iceland: a population-based study. Acta Derm Venereol 82 (2002) 467-469
7. Gupta A.K., Jain H.C., Lynde C.W., Watteel G.N., and Summerbell R.C. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists'; offices in Ontario, Canada-a multicenter survey of 2001 patients. Int J Dermatol 36 (1997) 783-787
8. Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch Dermatol 134 (1998) 1551-1554
9. Sporanox (itraconazole). [prescribing information] (2004), Janssen, Titusville, NJ
10. Lamisil (terbinafine HCl). [prescribing information] (2004), Novartis, East Hanover, NJ
11. Werschler W.P., Bondar G., and Armstrong D. Assessing treatment outcomes in toenail onychomycosis clinical trials. Am J Clin Dermatol 5 (2004) 145-152
12. De Cuyper C. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol 141 (1999) 15-20
13. Gupta A.K., Ryder J., and Summerbell R.C. Comparison of efficacy criteria across onychomycosis trials: need for standardization. Int J Dermatol 42 (2003) 312-315
14. Roberts D.T., and Evans E.G. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 138 (1998) 189-190
15. Scher R.K., and Baran R. Onychomycosis in clinical practice factors contributing to recurrence. Br J Dermatol 149 Suppl (2003) 5-9
16. Weinberg J.M., Koestenblatt E.K., Tutrone W.D., Tishler H.R., and Najarian L. Comparison of diagnostic methods in the evaluation of onychomycosis. J Am Acad Dermatol 49 (2003) 193-197
17. Elewski B.E., and Hay R.J. Update on the management of onychomycosis: highlights of the third annual international summit on cutaneous antifungal therapy. Clin Infect Dis 23 (1996) 305-313
18. Trepanier E.F., and Amsden G.W. Current issues in onychomycosis. Ann Pharmacother 32 (1998) 204-214
19. Elewski B.E. A full "cure" for onychomycosis is not always possible. Arch Dermatol 135 (1999) 852-853
20. Hay R.J. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 145 Suppl (2001) 3-8
21. Sigurgeirsson B., Olafsson J.H., Steinsson J.B., Paul C., Billstein S., and Evans E.G. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 138 (2002) 353-357
22. De Doncker P.D., Gupta A.K., Marynissen G., Stoffels P., and Heremans A. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 37 (1997) 969-974
23. Villars V.V., and Jones T.C. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 126 Suppl (1992) 61-69
24. Geyer A.S., Onumah N., Uyttendaele H., and Scher R.K. Modulation of linear nail growth to treat diseases of the nail. J Am Acad Dermatol 50 (2004) 229-234
25. Del Rosso J.Q. Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. J Am Osteopath Assoc 97 (1997) 339-346
26. Orentreich N., Markofsky J., and Vogelman J.H. The effect of aging on the rate of linear nail growth. J Invest Dermatol 73 (1979) 126-130
27. Jones H.E., and Zaias N. Double-blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. Int J Dermatol 35 (1996) 589-590